PR Newswire Clinical TrialsOriginal article
IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics
Positive
AI Analysis
Summary
IASO Biotechnology completed its acquisition of Singapore-based cell therapy company MediSix Therapeutics, an immune cell engineering and cell therapy company.
Outcome Details
Acquisition completed
Importance:7/10
Sentiment:
0.60
acquisitioncell therapyimmune cell engineeringSingaporeChina
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 13, 2026 11:06 AM